Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
Data Policies
EDITORIAL
Consensus Task Force recommendations
for evaluation and management
of Eosinophilic granulomatosis with
polyangiitis syndrome (Churg–Strauss)
1
Department of Pneumonology, “Sotiria” Chest
Diseases Hospital, Athens, Medical School,
National and Kapodistrian University of
Athens, Greece
2
1st Department of Pneumonology, “Sotiria”
Chest Diseases Hospital, Athens, Medical
School, National and Kapodistrian University
of Athens, Greece
Publication date: 2021-06-18
Corresponding author
Demosthenes Bouros
Medical School, National and Kapodistrian University of Athens, First Academic Department of Pneumonology, Hospital for Diseases of the Chest “Sotiria”, 152 Messogion Av., Athens 11527, Greece
Medical School, National and Kapodistrian University of Athens, First Academic Department of Pneumonology, Hospital for Diseases of the Chest “Sotiria”, 152 Messogion Av., Athens 11527, Greece
Pneumon 2015;28(4):324–326
KEYWORDS
REFERENCES (9)
1.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.
2.
Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy 2013;68:261-73.
3.
Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015;26:545-53.
4.
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–97.
5.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198–207.
7.
Kahn JE, Grandpeix-Guyodo C, Marroun I, et al. Sustained response to mepolizumab in refractory Churg–Strauss syndrome. J Allergy Clin Immunol 2010;125:267–70.
8.
Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid sparing treatment option in patients with Churg– Strauss syndrome. J Allergy Clin Immunol 2010;125:1336–43.
9.
Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg–Strauss syndrome. Ann Intern Med 2011;155:341–3.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.